Devil's Claw
A southern African root used for joint pain, standardized to harpagoside — an iridoid glycoside that is unstable in acid. That single property explains why the trial results split along formulation lines rather than dose lines, and why a capsule that dissolves in the stomach and one that does not are different products carrying the same number on the label.
Devil's Claw quick facts
| Suggested dose | Trials that worked used extracts delivering roughly 50–60 mg of harpagoside daily. Below about 30 mg the review evidence turns negative. |
| How often | Two to three times daily, because the half-life is hours |
| Who it's for | People with osteoarthritic joint pain or non-specific low back pain who want a non-NSAID option and can commit to weeks rather than days. |
Two numbers decide this, and most labels state neither clearly: milligrams of harpagoside rather than milligrams of extract, and whether the capsule protects the glycoside from stomach acid. The review evidence turns positive at roughly 50 to 60 mg of harpagoside daily and negative below about 30. Give it four to eight weeks. It is a bitter, so gastric upset is mechanistic rather than idiosyncratic, and it is the wrong herb for anyone with an active ulcer or gastritis. Interaction with warfarin is documented, effects on cardiac conduction are reported at high doses, and blood glucose falls modestly — all three matter more than the herb's gentle reputation implies.
How Devil's Claw actually works
The marker constituent is harpagoside, an iridoid glycoside from the secondary storage roots, and its chemistry sets the practical problem: the glycosidic bond is labile in gastric acid, so an unprotected capsule degrades a fraction of the dose before it reaches an absorptive surface. The anti-inflammatory pharmacology is better characterized than the herb's reputation suggests — in human osteoarthritis synoviocytes the root extract acts through CB2 receptor activation, and inhibition of COX-2 and iNOS expression is reported alongside it, so this is a receptor and transcription story rather than a generic antioxidant one. Whole extract consistently outperforms isolated harpagoside in models, which means either a second active constituent or a matrix effect on absorption; neither has been resolved, and it is the reason the systematic review evidence tracks extract dose rather than harpagoside purity.
Where to get Devil's Claw
Find Devil's Claw on iHerb →The evidence for Devil's Claw
Graded by what exists behind each claim.
✅ Clinically validated
- A systematic review of Harpagophytum procumbens in osteoarthritis and low back pain found moderate evidence of effectiveness for the higher-dose standardized extracts and insufficient evidence for the lower ones.
- A pilot randomized, triple-blind, placebo-controlled trial of a combination containing Harpagophytum in recreational runners with self-reported knee pain reported changes in pain outcomes, in a design that cannot separate the herbs from each other.
- In human osteoarthritis synoviocytes, root extract mediated anti-inflammatory effects through CB2 receptor activation — a specific receptor claim rather than a generic antioxidant one.
📊 Correlative data
- Namibian and South African traditional use for pain and digestive complaints predates the European clinical literature by a long way, and the bibliographic record traces how the modern phytopharmaceutical was built out of it.
🧪 Theoretical / extrapolated benefits
- Harpagoside is usually presented as the active constituent, but whole-extract preparations outperform isolated harpagoside in several models, which suggests either a second active or an absorption effect from the matrix. Neither has been resolved.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Devil's Claw actually does
The marker constituent is harpagoside, an iridoid glycoside stored in the secondary tubers of Harpagophytum procumbens, and its chemistry sets the practical problem before any pharmacology starts. Iridoid glycosides carry an acetal linkage that is labile in acid: at gastric pH a fraction of the dose hydrolyzes to an aglycone that rearranges into reactive products before it ever reaches an absorptive surface. Two capsules stating the same harpagoside content therefore deliver different amounts depending on whether the shell opened in the stomach or the small intestine.
The receptor pharmacology is better characterized than the herb's folk reputation suggests. In human osteoarthritis synoviocytes, root extract produced anti-inflammatory effects through CB2 receptor activation Mariano 2022. That is a named receptor in the diseased human cell type, which is a much stronger claim than the antioxidant language most joint herbs are sold on.
Downstream of that, the reported effects are transcriptional — suppression of NF-kappa-B-driven expression of COX-2, iNOS and matrix metalloproteinases, with reduced nitric oxide and prostaglandin E2 output. Crucially the extract does not inhibit cyclooxygenase enzyme activity the way an NSAID does; it lowers how much enzyme is made Gxaba 2022. That difference predicts a slower onset and a different gastric risk profile, and it matches what the trials show.
Whole extract consistently outperforms isolated harpagoside. That is reported across models and is the reason the systematic review evidence tracks extract dose rather than harpagoside purity Brendler 2021. Either a second constituent is active — the candidates are harpagide, procumbide and the phenylethanoid verbascoside — or the matrix protects the glycoside from acid. Neither has been resolved, and the two possibilities have different implications for formulation.
The bitter effect is a mechanism, not an inconvenience. Harpagoside is intensely bitter, and traditional use includes digestive complaints because bitters stimulate gastric secretion through vagal reflexes. That is why gastric upset with this herb is predictable rather than idiosyncratic, and why it is the wrong herb for an ulcer patient.
Cell, rodent, human — and where it stops
In human cells. Osteoarthritis synoviocytes, the cell type that produces the inflammatory mediators in an arthritic joint, respond to root extract through CB2 Mariano 2022. This is an unusually well-matched preparation for a botanical.
In people, the systematic review is the anchor and it is dose-split. A review of Harpagophytum procumbens in osteoarthritis and low back pain found moderate evidence of effectiveness for the higher-dose standardized extracts and insufficient evidence for the lower ones Gagnier 2004. The split falls at roughly 50 to 60 mg of harpagoside per day, and it is the single most useful number on this page.
In a modern randomized trial, and here is the obstacle. A pilot randomized, triple-blind, placebo-controlled trial in healthy recreational runners with self-reported knee pain tested a supplement combining Harpagophytum with Zingiber officinale and Bixa orellana Gonzalez-Gross 2021. Ginger has its own analgesic literature. A three-herb combination cannot attribute an effect to any one of them, and this is the recent trial most often cited for devil's claw specifically.
The second obstacle is chemotaxonomic and it is unusual. Two species are traded — H. procumbens and H. zeyheri — with different harpagoside content, and wild harvest from Namibia, Botswana and South Africa means batch variability is agricultural rather than manufactured Brendler 2021. A 2025 review asked bluntly whether the popular interest is justified by the evidence, which is the right question to ask of a herb whose good trials are twenty years old Bargsten 2025.
Devil's Claw — which form, and does it matter
Two numbers decide whether this works and most labels state neither clearly: milligrams of harpagoside, and whether the capsule survives the stomach.
Harpagoside, not extract. A 500 mg capsule of unstandardized root powder might carry 5 mg of harpagoside; a 400 mg extract standardized to 5 percent carries 20 mg. Reaching the 50 to 60 mg per day that the review evidence supports Gagnier 2004 means three capsules of the second product and an impossible number of the first. This is where most disappointment with the herb originates.
Acid protection is the second variable and almost nobody discusses it. Because the iridoid glycoside bond hydrolyzes at gastric pH, an enteric-coated or delayed-release presentation should deliver more intact harpagoside than a plain gelatin capsule of the same content. Aqueous and hydroethanolic extracts also differ in their iridoid to phenylethanoid ratio, and the trials used defined aqueous or hydroalcoholic extracts rather than whole powder Brendler 2021.
Exposure arithmetic and the timescale it implies. Harpagoside absorption is modest and its plasma half-life is on the order of hours, which is why the trials dosed two or three times daily rather than once. Because the proposed mechanism is transcriptional rather than direct enzyme inhibition Gxaba 2022, the effect builds over weeks: four to eight weeks is the honest trial period, and a three-day verdict is meaningless.
Species matters. H. zeyheri is a legitimate but different plant with a different iridoid profile, and it is traded alongside H. procumbens. A label that names only 'devil's claw' has not told you which one is in the bottle.
What would have to be true, and how you would know it was not
The efficacy prediction is a pain and function score, run against a written baseline. WOMAC or a simple 0 to 10 pain score plus morning stiffness duration, recorded for two weeks before starting and at four and eight weeks after. The review evidence predicts movement at 50 to 60 mg of harpagoside daily and no movement below 30 Gagnier 2004, which makes the dose a testable variable rather than a preference.
The prediction that would separate this from an NSAID. If the mechanism is transcriptional suppression of COX-2 expression rather than active-site inhibition Gxaba 2022, then onset should be days to weeks rather than hours, and stopping should produce a slow return of symptoms rather than an immediate one. Somebody who reports relief within an hour of the first capsule is describing something this mechanism does not predict.
The safety predictions are two numbers on a routine panel. Fasting glucose should drift down slightly, because a modest hypoglycemic effect is reported; and in anybody on warfarin, INR should be checked within two weeks of starting, because the interaction is documented Brendler 2021. Both are cheap and both are the kind of thing nobody checks on a herb with a gentle reputation.
What nobody has tested yet
Nobody has run a modern, adequately powered, single-herb trial at the dose the old review supports. The strongest evidence is a 2004 systematic review Gagnier 2004; the most-cited recent trial is a three-herb combination Gonzalez-Gross 2021; and the 2025 literature is still asking whether the popular interest is justified Bargsten 2025. Twenty years is a long time for an obvious trial not to have been done.
The whole-extract-beats-harpagoside observation has never been explained. Second active constituent or matrix protection are distinguishable experimentally — compare an acid-protected isolated harpagoside against whole extract at matched harpagoside content — and the answer would tell manufacturers what to standardize to Brendler 2021.
And the CB2 finding has not been followed into a person. A cannabinoid receptor mechanism in human synoviocytes Mariano 2022 predicts specific things — additivity or redundancy with other CB2 ligands, and a possible effect on the inflammatory infiltrate rather than on pain perception alone — and none of them has been tested clinically.
Devil's Claw — its own safety story, not its category's
The reputation is gentle and the interaction list is not.
Gastric upset is mechanistic. This is a bitter that stimulates gastric acid secretion, so dyspepsia is the predicted adverse effect rather than an unlucky one, and active peptic ulcer or gastritis is a contraindication rather than a caution.
Warfarin interaction is documented, and purpura has been reported Brendler 2021. Anyone on an anticoagulant who starts this needs an INR check inside two weeks.
Cardiac effects at high doses have been described — effects on heart rate and on conduction — which puts it in an awkward place beside antiarrhythmics and digoxin. This is not a well-quantified risk and that is exactly why it belongs in the safety section rather than being left out.
Blood glucose falls modestly, which is additive with sulfonylureas, insulin and other glucose-lowering agents.
Avoid in pregnancy. Oxytocic activity is described in both the traditional and the preclinical literature Gxaba 2022.
And a supply-chain note that is a safety note. Devil's claw is wild-harvested from southern Africa and is subject to conservation controls; wild harvest also means botanical substitution with H. zeyheri is a real possibility, and a product that does not name the species has not told you what you are taking Brendler 2021.
Sources read for this page
- Gagnier JJ. Harpgophytum procumbens for osteoarthritis and low back pain: A systematic review. BMC Complement Altern Med 2004 · PMID 15369596
- Mariano A. Harpagophytum procumbens Root Extract Mediates Anti-Inflammatory Effects in Osteoarthritis Synoviocytes through CB2 Activation. Pharmaceuticals (Basel) 2022 · PMID 35455454
- Gxaba N. The Fight against Infection and Pain: Devil's Claw (Harpagophytum procumbens) a Rich Source of Anti-Inflammatory Activity: 2011-2022. Molecules 2022 · PMID 35684573
- Brendler T. From Bush Medicine to Modern Phytopharmaceutical: A Bibliographic Review of Devil's Claw (Harpagophytum spp.). Pharmaceuticals (Basel) 2021 · PMID 34451822
- Gonzalez-Gross M. Analysis of Effectiveness of a Supplement Combining Harpagophytum procumbens, Zingiber officinale and Bixa orellana in Healthy Recreational Runners with Self-Reported Knee Pain: A Pilot, Randomized, Triple-Blind, Placebo-Controlled Trial. Int J Environ Res Public Health 2021 · PMID 34067240
- Bargsten FE. Devil's claw (Harpagophytum procumbens): is the buzz in Google justified?. Naunyn Schmiedebergs Arch Pharmacol 2025 · PMID 40042557
How you would know if it worked
There is no blood test for this one. That is not a criticism — it is a fact about the effect, and it changes how you should judge it.
- What to watch: A pain score and morning stiffness duration for the specific joint, logged for two weeks before starting. Note the harpagoside milligrams on the label at the same time — the review evidence turns positive around 50 to 60 mg a day and negative below 30, so the dose is part of the experiment rather than a fixed setting.
- How long before it means anything: Four to eight weeks. The proposed mechanism is suppression of COX-2 expression rather than inhibition of the enzyme itself, so the effect should build over weeks. Relief inside an hour of the first capsule is not what this pharmacology predicts.
- What will fool you: Osteoarthritis flares and settles on its own, and people start a new supplement at the worst point of a flare. The other one is the combination product: most recent trial material pairs this root with ginger, which has its own analgesic literature, and a three-herb capsule cannot tell you which herb did anything.
Run it one variable at a time. Starting three things in one week means a result you cannot attribute, which is the same as no result.
Devil's Claw — safety & side effects
- GI upset is the common complaint and it is mechanistic — this is a bitter used traditionally to stimulate gastric secretion.
- Avoid with active peptic ulcer or gastritis, for the same reason.
- Documented interaction potential with warfarin, plus effects on cardiac conduction reported at high doses; caution with antiarrhythmics and with digoxin.
- It lowers blood glucose modestly — additive with diabetes medication.
- Avoid in pregnancy: oxytocic activity is described in the traditional and preclinical literature.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Devil's Claw in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Devil's Claw
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Ferritin | Below 50 and hair and skin repair suffer, whatever else you take |
| Vitamin D (25-Hydroxy) | Skin, bone and connective tissue all depend on it |
| TSH (Thyroid-Stimulating Hormone) | Thyroid disease shows in hair, skin and nails first |
| Zinc, Plasma | Deficiency causes poor wound healing and hair shedding |
The Basics — Start Here panel covers these in one order — 4 markers, $32.40 with the discount applied.
Check results you already have → · All 103 markers A–Z
Devil's Claw — frequently asked questions
What is Devil's Claw?
A southern African root used for joint pain, standardized to harpagoside — an iridoid glycoside that is unstable in acid. That single property explains why the trial results split along formulation lines rather than dose lines, and why a capsule that dissolves in the stomach and one that does not are different products carrying the same number on the label.
What is the suggested dose of Devil's Claw?
Trials that worked used extracts delivering roughly 50–60 mg of harpagoside daily. Below about 30 mg the review evidence turns negative. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Devil's Claw dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Devil's Claw?
Coach Cam sources Devil's Claw from vetted, top-rated brands on iHerb — use the buy link on this page.
What Devil's Claw is used for
Devil's Claw appears under 1 goal in the goal router.
Related Skin & Structural supplements
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.